Aurora Cannabis (ACB) Q2 2025: International Medical Cannabis Revenue Jumps 93% as Global Shift Accelerates
International medical cannabis now surpasses domestic sales as Aurora’s core profit engine, driven by regulatory wins and product innovation in Europe and Australia. Margin gains and cash discipline position ACB for sustainable growth, but consumer cannabis and plant propagation remain secondary. Visibility into global medical demand and regulatory barriers underpin a bullish long-term thesis, even as market lumpiness and policy risk persist.
Summary
- Global Medical Pivot: Aurora’s international medical business now accounts for the majority of segment revenue and margin.
- Margin Outperformance: Improved operating efficiency and premium pricing drive record profitability.
- Cash Strength: Debt-free cannabis operations and positive free cash flow signal strategic flexibility ahead.
Business Overview
Aurora Cannabis is a vertically integrated cannabis company focused on medical cannabis, consumer cannabis, and plant propagation. Revenue is primarily generated through the sale of medical cannabis products to patients in Canada and internationally, with additional contributions from a small Canadian recreational (adult-use) business and Bevo, its controlled-environment plant propagation segment. Medical cannabis is the high-margin flagship, now representing over three-quarters of total sales and nearly all gross profit.
Performance Analysis
Aurora delivered a step-change in profitability and global revenue mix, with net revenue up sharply and record results in both adjusted gross profit and EBITDA. Medical cannabis revenue surged 41% year-over-year, underpinned by 93% international growth as Australia, Germany, Poland, and the UK contributed outsized gains. The international medical segment now accounts for 57% of global medical cannabis revenue, up from a minority share last year, and 76% of total company revenue. Adjusted gross margin for medical cannabis climbed to 68%, with consolidated margins also expanding, reflecting both higher pricing and cost discipline.
Canadian medical cannabis grew modestly, and the company maintained its leadership in this mature market. In contrast, consumer cannabis revenue declined as Aurora prioritized high-margin medical supply, while the Bevo plant propagation business delivered double-digit organic growth despite seasonality. SG&A rose, mainly from the MedRelief Australia acquisition, but was offset by incremental EBITDA. Cash burn improved, with Aurora ending the quarter with a robust $152 million cash balance and no debt in its cannabis segment.
- International Medical Inflection: Overseas revenue now exceeds Canadian medical, signaling a global shift in Aurora’s profit model.
- Margin Expansion: Cost reductions, premium pricing in Australia, and operational efficiency drive gross margin above targets.
- Consumer Cannabis Deprioritized: Lower sales and margins reflect Aurora’s strategic focus on medical and away from low-return recreational.
Overall, the quarter validates Aurora’s medical-first, global strategy, but also exposes ongoing volatility in shipment timing, regulatory complexity, and the limited role of consumer cannabis in the profit mix.
Executive Commentary
"The contribution from high-margin international revenue exceeded that of Canadian medical cannabis for the first time and amounted to 57% of total global medical cannabis revenue. This shift demonstrates how we have successfully positioned ourselves to benefit from opportunities across the globe."
Miguel Martin, Executive Chairman and CEO
"Quarterly profitability consisted of consolidated adjusted gross margin at 54%, 300 basis points higher than last year, resulting in a record adjusted gross profit of $42.6 million. Adjusted EBITDA grew 210% to $10.1 million, a new record for the company and our eighth consecutive quarter of positive adjusted EBITDA."
Simona King, CFO
Strategic Positioning
1. Global Medical Cannabis Leadership
Aurora’s core strategy is to dominate the globally regulated medical cannabis market, leveraging its EU GMP (Good Manufacturing Practice, a pharmaceutical quality standard) and TGA GMP (Australian regulatory certification) facilities. This enables access to high-barrier markets like Germany and Australia, where regulatory compliance is a moat and premium pricing is achievable.
2. Portfolio Rationalization and Margin Focus
The company has intentionally deprioritized Canadian recreational cannabis, maintaining a small presence for consumer insights and product innovation but focusing capital and operational resources on high-margin medical segments. This approach is reflected in the declining revenue and margin from consumer cannabis, and the company’s willingness to let market share fall in favor of profitability.
3. Operational Efficiency and Balance Sheet Strength
Cost discipline and capital allocation remain central, as Aurora operates debt-free in its cannabis business and is on track for positive free cash flow. Investments are targeted at internal innovation, facility upgrades, and opportunistic M&A, particularly as global valuations reset. SG&A increases from acquisitions are being offset by incremental profit, with working capital tightly managed.
4. Product Innovation and Market Diversification
New product launches, such as CBD lozenges and premium oils, are tailored to local market needs, with genetics and breeding programs supporting differentiated offerings. The company’s presence in multiple geographies (Canada, Australia, Germany, Poland, UK) provides revenue smoothing and early entry into emerging medical markets.
5. Plant Propagation as a Diversification Lever
Bevo, the plant propagation segment, provides a non-cannabis revenue stream and operational optionality. While seasonally weaker in Q2, Bevo’s capacity expansion and product diversification (e.g., orchids) are intended to drive growth and offset cannabis cyclicality, though margins remain lower than the core medical segment.
Key Considerations
Aurora’s Q2 marks a structural shift in revenue mix and margin profile, but the durability of these gains depends on regulatory and market dynamics across multiple regions. Investors should weigh the following:
Key Considerations:
- International Medical Demand: Sustained patient growth and regulatory liberalization in Australia and Europe are driving global medical revenue above domestic levels.
- Regulatory Barriers as Moat: EU GMP and TGA GMP certification create high entry barriers, but also expose Aurora to policy and permit-driven shipment lumpiness.
- Cash and Capital Allocation: Strong liquidity and no cannabis debt allow for opportunistic investment, but management remains focused on internal returns and selective M&A.
- Consumer Cannabis Role: Recreational remains a minor, strategically useful segment, with no near-term ambition to scale given margin headwinds.
- Plant Propagation Upside: Bevo’s growth and diversification are positives, but the segment is still a small contributor and subject to seasonal swings.
Risks
Shipment timing and regulatory approval cycles create revenue volatility, especially in emerging international markets where import permits can delay sales. Policy risk remains material, as changes in medical or recreational frameworks (especially in Germany or Australia) could shift market dynamics. Margin sustainability depends on continued premium positioning and cost control, while competitive intensity and price pressure in mature markets could erode gains. Bevo’s seasonality and lower margin profile add further variability to consolidated results.
Forward Outlook
For Q3 2025, Aurora guided to:
- Similar sequential net revenue and adjusted gross margins across global medical cannabis, with year-over-year growth in Europe and Australia.
- Seasonally reduced revenues and gross profit for plant propagation, consistent with historical trends.
For full-year 2025, management maintained its outlook for:
- Continued positive adjusted EBITDA and positive free cash flow in Q3.
Management highlighted several factors that support the outlook:
- Full recognition of Australian revenue post-acquisition and further European growth.
- Disciplined working capital and operating expense management to sustain margin targets.
Takeaways
Aurora’s Q2 cements its transformation into a global medical cannabis leader, with international revenue and margins now driving the business.
- International Medical Is Now the Core Engine: With 57% of global medical revenue from outside Canada, Aurora’s future is tied to regulatory and patient growth in Europe and Australia.
- Margin and Cash Discipline Are Delivering: Record profitability, no debt, and a strong cash position provide strategic flexibility and downside protection.
- Future Watchpoints: Track international shipment consistency, regulatory developments in key markets, and progress toward sustained free cash flow and capital deployment.
Conclusion
Aurora’s results reflect a decisive pivot to international medical markets, with structural margin and cash flow improvements. Execution risk remains, but the business is now positioned for sustainable, high-quality growth as global medical adoption accelerates.
Industry Read-Through
Aurora’s quarter is a clear signal that global medical cannabis is outpacing domestic recreational markets in both growth and profitability. Companies with EU GMP and TGA GMP manufacturing capabilities are best positioned to win in highly regulated, high-margin markets like Germany and Australia, while those focused on recreational face ongoing price and margin compression. Regulatory complexity and shipment lumpiness will remain a feature of international medical, but successful operators will use geographic diversification and compliance expertise as a moat. Plant propagation diversification is a secondary lever, providing some revenue smoothing but not a primary value driver. For the broader cannabis sector, the path to sustainable profit is now clearly medical-first, global, and compliance-driven.